Evommune (EVMN) Short-term Investments (2024 - 2026)

Evommune (EVMN) has reported Short-term Investments for 3 consecutive years, with $163.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments changed N/A year-over-year to $163.1 million; the TTM figure through Mar 2026 stood at $163.1 million (changed N/A YoY), while the FY2025 annual figure was $105.1 million, up 88.47% from the prior year.
• Short-term Investments climbed to $163.1 million in Q1 2026 per EVMN's latest filing, from $105.1 million in the prior quarter.
• Across five years, Short-term Investments topped out at $163.1 million in Q1 2026 and bottomed at $49.2 million in Q3 2025.
• Historically, Short-term Investments has averaged $93.3 million across 3 years, with a median of $80.5 million in 2024.
• On a YoY basis, Short-term Investments climbed as much as 88.47% in 2025 and fell as far as 88.47% in 2025.
• Evommune's Short-term Investments stood at $55.8 million in 2024, then jumped by 88.47% to $105.1 million in 2025, then soared by 55.17% to $163.1 million in 2026.
• Business Quant data shows EVMN's Short-term Investments at $163.1 million in Q1 2026, $105.1 million in Q4 2025, and $49.2 million in Q3 2025.